HomeAI · summaries
Storia in 3 fonti
SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease
SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
healio.com
Pediatric Dermatology News
Find the latest Pediatric Dermatology news articles, videos, podcasts, and meeting coverage from medical experts and key opinion leaders you trust.
- ·
FDA approves Skyrizi for pediatric use in psoriatic disease
The FDA approved risankizumab-rzaa for children aged at least 6 years with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy or active…
- ·
morningstar.com
SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease
SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease
- ·
medpagetoday.com
FDA Expands Risankizumab Label in Psoriatic Disease
IL-23 inhibitor lands indications for kids 6 years and up